Genmab — April 2019

[Sukkeralf]

ClinicalTrials.gov

(clinicaltrials.gov)

[Solsen]

Han sagde, at han ville udlicitere cd20/Cd3 og han ønskede ikke at konkurrere med Roche igen på et cd20 stof.

[transalp]

Go morgen..

[JohnW]

God morgen. Tør man håbe på en MAIA-nyhed i dag?

[Vitus]

Det sker der skam ikke noget ved

[polle1]

Rart (og helt usædvanligt) at se at GEN ligger i top i C25 !

[Vitus]

Ja, det er da en fornøjelse..og den må gerne fortsætte op.....

[polle1]

CELG kom med et meget fint regnskab iaftes

[Bella1]

Måske katten er ude af sækken?

[Bella1]

• eller knuden er ved at løsne sig....

[polle1]

Som jeg sagde igår, så er der noget undervejs, omsætning idag de første 40 minutter ca. det samme som på 7 timer igår !!

[JohnW]

Jeg tror det er MAIA, som ligger klar når FDA åbner.

[E_L]

SGEN had quarterly earnings yesterday and said a few words about Tisotumab. Nothing we don't know yet I think. transcript: https://seekingalpha.com/article/4256999-seattle-genetics-inc-sgen-ceo-clay-siegall-q1-2019-results-earnings-call-transcript?part=single

[E_L]

i'll post the main paragraph:

[E_L]

Tisotumab vedotin or TV is and ADC that we are developing in partnership with Genmab. We are conducting a pivotal Phase 2 single-arm single-agent trial for women with recurrent or metastatic cervical cancer which has recently completed enrollment and is designed to support a regular submission under the FDA's accelerated approval mechanism.

[E_L]

The primary endpoint of this trial is confirmed objective response rate by independent review. Updated data from the Phase 1 trial were recently reported at the Society of Gynecologic Oncology annual meeting showing a 22% confirmed objective response rate by independent review with a median duration of response of six months.

[E_L]

The safety profile of TV was as previously reported. We remain encouraged by the data in the setting where there is no standard of care and outcomes are poor.

[E_L]

We and Genmab are also evaluating TV in combination with other agents to inform our strategy of moving TV into earlier lines of cervical cancer. Further, we are enrolling patients in trials of TV with other solid tumors.

[E_L]

end quote

[Bulder]

Nice to hear that they have designed the trial for RTOR.